Entries by

Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter 2020 and Recent Business […]

Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis

March 23, 2021 07:30 AM Eastern Daylight Time NEW YORK & CHICAGO–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology, and EVERSANA™, the pioneer of next-generation commercial services to the global life sciences industry, today announced a partnership to help […]

EYENOVIA TO REPORT FOURTH QUARTER AND FULL YEAR 2020 RESULTS ON THURSDAY, MARCH 25

NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, March 25, 2021, after market close. Following […]

Eyenovia to Participate in the 33rd Annual Roth Conference

NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will participate in the 33rd Annual Roth Conference, which will be held on March 15-17, 2021. Management will […]

Eyenovia Announces FDA Acceptance of the MydCombi NDA

March 02, 2021 07:30 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for MydCombi™, a unique fixed combination mydriatic (pupil dilation) […]